Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.

Juweid, M E

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. [electronic resource] - Cancer Apr 1999 - 1828-42 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.

0008-543X

10.1002/(sici)1097-0142(19990415)85:8<1828::aid-cncr25>3.0.co;2-h doi


Adult
Aged
Aged, 80 and over
Animals
Antibodies, Anti-Idiotypic--biosynthesis
Antibodies, Monoclonal--pharmacokinetics
Antibodies, Monoclonal, Humanized
Antigens, Neoplasm--immunology
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Calcitonin--blood
Carcinoembryonic Antigen--immunology
Carcinoma, Medullary--drug therapy
Combined Modality Therapy
Female
Humans
Immunoconjugates--pharmacokinetics
Iodine Radioisotopes--administration & dosage
Male
Metabolic Clearance Rate
Mice
Middle Aged
Neck Dissection
Neoplasm Proteins--blood
Radioimmunotherapy
Radiotherapy Dosage
Thyroid Neoplasms--drug therapy
Thyroidectomy
Tissue Distribution
Treatment Outcome